Crushed by a PhIII flop, Novavax slashes jobs as it looks to chop out up to $100M in costs
Two months ago, shares of Novavax $NVAX were crushed when the biotech was forced to concede that its big Phase III study for an RSV …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
